Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway

1 Mar 2021

Abstract excerpt

BACKGROUND: is an oncogene that encodes the p110α subunit of class IA PI3K to regulate cell proliferation and apoptosis. Some reports have observed neoadjuvant chemotherapy (NAC) to have poor pathological complete response (pCR) rates in TNBC with PIK3CA mutation. This study aimed to explore the mechanism of how mutant PIK3CA alters chemotherapeutic susceptibility in TNBC. METHODS: experiments. Epirubicin was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33842631
DOI: 10.21037/atm-21-698

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathwayPMID 33842631Read ↗

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.Semantic proximity Read ↗

Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.Semantic proximity Read ↗

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted TherapeuticsSemantic proximity Read ↗

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.Semantic proximity Read ↗

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)Semantic proximity Read ↗

Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent ApoptosisSemantic proximity Read ↗

Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1Semantic proximity Read ↗

Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1Semantic proximity Read ↗

Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).Semantic proximity Read ↗

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive ReviewSemantic proximity Read ↗

Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.Semantic proximity Read ↗

Analysis of PIK3CA Mutations with Clinicopathological Features and Prognosis in Breast cancer patients with Undergoing Neoadjuvant TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.